Paper

Efficacy and safety of deucravacitinib, an oral, selective tyrosine kinase 2 inhibitor, in patients with active psoriatic arthritis: 52-week results from the randomised, double-blind, placebo-controlled phase 3 POETYK PsA-1 trial

Annals of the Rheumatic Diseases · 2026 · Désirée van der Heijde, Philip J Mease, Carle Paul et al.